Clinical and Translational Research Section

Editorial: New Clinical and Translational Research Section of "Science, Public Health Policy & The Law"

A Novel Approach to Treating COVID-19 Using Nutritional and Oxidative Therapies

?David Brownstein, M.D., Richard Ng, M.D., Robert Rowen, M.D., Jennie-Dare Drummond, PA, Taylor Eason, NP, Hailey Brownstein, D.O., and Jessica Brownstein

?Correspondence: info@drbrownstein.com

Abstract

Objective: This report is a case series of consecutive patients diagnosed with COVID-19 treated with a nutritional and oxidative medical approach. We describe the treatment program and report the response of the 107 COVID-19 patients.

Study Design: Observational case series consecutive.
 

Setting: A family practice office in a suburb of Detroit, Michigan.
 

Patients: All patients seen in the office from February through May 2020 diagnosed with COVID-19 were included in the study. COVID-19 was either diagnosed via PCR or antibody
testing as well as those not tested diagnosed via symptomology.
Interventions: Oral Vitamins A, C, D, and iodine were given to 107 subjects (99%). Intravenous solutions of hydrogen peroxide and Vitamin C were given to 32 (30%) and 37 (35%) subjects. Thirty-seven (35%) of the cohort was treated with intramuscular ozone. A dilute, nebulized hydrogen peroxide/ saline mixture, with Lugol's iodine, was used by 91 (85%).
Main Outcome Measures: History and physical exam were reviewed for COVID-19 symptoms including cough, fever, shortness of breath, and gastrointestinal complaints. Laboratory reports were examined for SARS-CoV-2 results. Symptomatic improvement after treatment was reported for each patient consisting of first improvement, mostly better, and completely better. 

Results: There were a total of 107 patients diagnosed with COVID-19. Thirty-four were tested for SARS-CoV-2(32%) and twenty-seven (25%) tested positive. Three were hospitalized (3%) with two of the three hospitalized before instituting treatment and only one requiring hospitalization after beginning treatment. There were no deaths. The most common symptoms in the cohort were fever (81%), shortness of breath (68%), URI which included cough (69%), and gastrointestinal distress symptoms (27%). For the entire cohort, first improvement was noted in 2.4 days. The cohort reported symptoms mostly better after 4.4 days and completely better 6.9 days after starting the program. For the SARS-CoV-2 test positive patients, fever was present in 25 (93%), shortness of breath in 20 (74%) and upper respiratory symptoms including cough in 21 (78%) while gastrointestinal symptoms were present in 9 (33%). The time to improvement in the SARS-CoV-2 test positive group was slightly longer than the entire cohort.
 

Conclusion: At present, there is no published cure, treatment, or preventive for COVID-19 except for a recent report on dexamethasone for seriously ill patients. A novel treatment program combining nutritional and oxidative therapies was shown to successfully treat the signs and symptoms of 100% of 107 patients diagnosed with COVID-19.
Each patient was treated with an individualized plan consisting of a combination of oral, IV, IM, and nebulized nutritional and oxidative therapies which resulted in zero deaths and recovery from COVID-19.